Exchange: NYSE·Updated 09:54 AM EDT
News
all
press releases
Chief Financial Officer At Stevanato Group Sells $84K Of Stock
Revealing a significant insider sell on August 10, Marco Lago Dal, Chief Financial Officer at Stevanato Group (NYSE:STVN), as per the latest SEC filing. What Happened: Dal's recent Form 4 filing with the U.S.read more...
Benzinga
More News
Is Stevanato (STVN) a Solid Growth Stock? 3 Reasons to Think "Yes"
Stevanato (STVN) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Zacks
Stevanato Group (STVN) Q2 Earnings Top Estimates
Stevanato (STVN) delivered earnings and revenue surprises of +6.67% and -0.08%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Stevanato Group Delivers 8% Revenue Growth for the Second Quarter of Fiscal 2026
Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the second quarter of 2026. Second Quarter of 2026 Highlights...
Business Wire
Liraglutide Combination Products Incorporating Stevanato Group's Alina Pen Injector Received Marketing Authorizations in Multiple European Countries
Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery and diagnostic solutions for the pharmaceutical, biotechnology and life sciences industries, today announced that liraglutide-based combination products incorporating Stevanato Groups proprietary Alina...
Business Wire
Ionis Pharmaceuticals (IONS) Reports Q2 Loss, Tops Revenue Estimates
Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of +51.69% and +40.52%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Stevanato Group to Report Second Quarter 2026 Financial Results on August 4, 2026
Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the second quarter of 2026 on Tuesday, August 4...
Business Wire
Profound Medical (PROF) Moves 8.2% Higher: Will This Strength Last?
Profound Medical (PROF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zacks
TimesSquare Mid Cap Growth Strategy Downplays Market Fears on Stevanato Group S.p.A. (STVN)
TimesSquare Mid Cap Growth Strategy Downplays Market Fears on Stevanato Group S.p.A. (STVN...
Yahoo! Finance: News
Aurinia (AUPH) Moves 6.5% Higher: Will This Strength Last?
Aurinia (AUPH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Zacks

Advertisement|Remove ads.